Sanyou Bio Unveils New Monkeypox Antigens, Antibodies, and Cell Lines

On August 28, 2024, Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. unveiled an extensive product line dedicated to combating monkeypox. This new range includes 65 items categorized into three main types: 26 natural epitope antigens, 28 high-affinity monoclonal antibodies, and 11 overexpression cell lines. These products are designed to target critical sites on the monkeypox virus, such as A29L, M1R, and E8L, among others essential for viral infection and assembly.

The monoclonal antibodies, developed using Sanyou Bio's proprietary "over-trillion innovative antibody discovery" platform, cover various species, including fully human, nano, and mouse antibodies. These antibodies are crucial for advancing therapeutic drug development, with high-affinity nano antibodies offering significant value for structural analysis and bispecific research. In addition, the antigens and cell lines can be utilized for diagnostic reagents and scientific research.

Dr. Lang Guojun, CEO of Sanyou Bio, highlighted the company’s agile response during the COVID-19 pandemic, where Sanyou Bio made notable contributions to antibody therapy development, with their work featured in top scientific journals and advancing to clinical trials. With this new monkeypox product line, Sanyou Bio aims to enhance the development of vaccines, therapeutics, and diagnostic tools, reinforcing its commitment to global public health.

About Sanyou Bio: 

Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. is a leading biopharmaceutical company specializing in the discovery and development of innovative antibody-based therapies. Known for its advanced antibody discovery platforms and significant contributions to public health, Sanyou Bio has played a pivotal role in developing therapies for various viral diseases, including COVID-19. The company is dedicated to advancing therapeutic, diagnostic, and research solutions to address critical global health challenges.